CODX logo

Co-Diagnostics, Inc.

CODX
Healthcare|Biotechnology|US
$0.26
-0.01 (-3.86%)
DCF Value
$7.41
Tangible Book / Share
$1.27
Cash / Share
$0.85

About

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Stock Price

-97.8%(1Y)
1M
-76.4%
3M
-83.1%
6M
-89.8%
YTD
-94.9%
1Y
-97.8%
3Y
-99.3%
5Y
-99.9%

Pipeline Summary

501 total trials
14
Phase 1
38
Phase 2
26
Phase 3
18
Phase 4
Withdrawn: 17Terminated: 32Completed: 260Unknown: 78Not Yet Recruiting: 18Recruiting: 63Active: 24Suspended: 3By Invitation: 4No Longer Available: 1Temporarily Unavailable: 1

Active Trials (87)

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
NCT06048094Brain Metastases
Phase 1Recruiting
Enrollment: 46 participants
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
NCT07393867Intermediate Risk Prostate Cancer
Phase 2Recruiting
Enrollment: 23 participants
An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.
NCT06070688Respiratory Tract Infections
N/ARecruiting
Enrollment: 100 participants
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
NCT03704766Joint Infection
N/ARecruiting
Enrollment: 442 participants
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
NCT07455903Prostate Cancer
Phase 2Recruiting
Enrollment: 50 participants

Key Facts

Market Cap$1.9M
Employees115 (-13% YoY)
CEODwight Egan
IPO DateJul 12, 2017
Beta3.20
52-Week Range$0.245 – $13.54
Avg Volume372,578
ExchangeNASDAQ
Websiteco-dx.com

Ownership

Float82.7%
Shares Outstanding7.4M

Recent Insider Trades

Bohrer DanielOTHER
Sep 2, 20260 shares
Egan Dwight HAWARD
May 23, 20264,584 shares
Egan Dwight HDISPOSED
May 23, 20261,633 shares @ $5.07
Egan Dwight HOPTION EX.
May 23, 20264,584 shares
Brown Brian LeeAWARD
May 23, 20263,750 shares

Peers

ADGMAdagio Medical Holdings, Inc.
$1.8M
AEMDAethlon Medical, Inc.
$2.9M
ALURAllurion Technologies Inc.
$1.0K
DWTXDogwood Therapeutics, Inc.
$48.9M
NVNOenVVeno Medical Corporation
$4.7M
PRPHProPhase Labs, Inc.
$140.2K
SINTSintx Technologies, Inc.
$11.1M
TNONTenon Medical, Inc.
$814.2K
Data last updated: Nov 9, 2026, 04:03 AM